New RO 7.7 Million Pharma Plant in Sohar Free Zone: Boosting Investment Opportunities for Businesses in Oman
Suhar, November 3 — SOHAR Port and Freezone has entered into a land lease agreement with the Investment Group for Pharmaceutical Industries, a Free Zone entity, to construct a cutting-edge pharmaceutical and medical supplies manufacturing facility on a 40,000-square-metre site. This project, valued at approximately RO 7.7 million (around $20 million), represents a significant development in Oman’s industrial and healthcare sectors.
The facility is a collaborative effort between Omani investors and Algeria’s IMGSA Group, underscoring SOHAR’s dedication to fostering a sustainable and investment-friendly environment that promotes trade and innovation. Operations are expected to commence in 2027, with the plant designed to adhere to stringent international manufacturing standards.
This factory will be equipped with sterile production lines, state-of-the-art quality control laboratories, research and development units, and a dedicated training center aimed at cultivating local expertise in pharmaceutical production and quality management. It will manufacture a diverse array of medical products, including antibiotics, oncology treatments, medical gloves, sterile gauze, and various healthcare consumables.
Dr. Tawfiq Houam, Chairman and CEO of IMGSA Group, and co-founder of the investment consortium, stated that SOHAR was selected for its “strategic location, advanced infrastructure, and integrated industrial ecosystem.” He emphasized that the project intends to enhance research, innovation, and talent development while advancing Oman’s self-sufficiency in healthcare and establishing the nation as a regional pharmaceutical hub.
Eng. Raed bin Mohammed al Rubaie, CEO of SOHAR Free Zone and Deputy CEO of Sohar Port, remarked that this project is “a strategic addition to the Free Zone’s portfolio of advanced industries.” He highlighted its potential to strengthen local and regional pharmaceutical supply chains and align with the objectives of Oman Vision 2040, thereby expanding the base of sustainable industrial production. — ONA
Special Analysis by Omanet | Navigate Oman’s Market
The establishment of a $20 million pharmaceutical manufacturing plant at SOHAR Port signals significant growth for businesses in Oman’s healthcare sector. This project not only enhances local supply chains but also positions Oman as a potential regional pharmaceutical hub, opening lucrative opportunities for investors and entrepreneurs in the pharmaceutical and adjacent industries. Smart stakeholders should consider the impending demand for locally produced medical supplies and align their strategies with Oman Vision 2040’s focus on self-sufficiency and innovation.
